dihexa safety concerns hgf c-met cancer risk Frontiers Dihexa (PNB-0408) | c-Met/HGFR Activator
Dihexa (PNB 0408) c Met HGFR Activator MedChemExpress Developing c MET pathway inhibitors for cancer therapy: progress and challenges: Trends in Molecular Medicine Targeting HGF c MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion Cell Communication and Signaling Springer Nature Link Targeting cancer associated fibroblast activated HGF c MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity ScienceDirect Combination of HGF MET targeting agents and other therapeutic strategies in cancer ScienceDirect
Pay in 4 interest-free payments of $6.96 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




